New Therapies for Hepatitis C Virus Infection
New Therapies for Hepatitis C Virus Infection
复制标题
DOI：
10.1086/595848
复制
发表时间：
2009-02-01
影响因子：
11.8
通讯作者：
Zeuzem, Stefan
中科院分区：
文献类型：
--
作者：
Soriano, Vincent;Peters, Marion G.;Zeuzem, Stefan
慢性丙型肝炎病毒（HCV）感染仍然是一个全球性的健康威胁，全球约有1.75亿携带者。目前，治疗包括聚乙二醇干扰素α加利巴韦林12-72周，这取决于HCV基因型、基线病毒载量和对治疗的初始病毒学应答。严重的不良反应和有限的持续病毒学反应，这种治疗保证了新的HCV治疗的需要。旨在抑制HCV丝氨酸蛋白酶和RNA依赖性RNA聚合酶的特异性靶向抗病毒疗法最近已进入临床开发。在此，这些新的抗病毒药剂的主要特点和最重要的挑战，与他们的使用，即毒性和快速选择耐药性进行了讨论。
Chronic hepatitis C virus (HCV) infection remains a global health threat with similar to 175 million carriers worldwide. Currently, treatment consists of pegylated interferon alfa plus ribavirin for 12-72 weeks, depending on HCV genotype, baseline viral load, and initial virological response to therapy. Serious adverse effects and limited sustained virological responses with this therapy warrant the need for novel HCV therapies. Specifically targeted antiviral therapies designed to inhibit the HCV serine protease and the RNA-dependent RNA polymerase have recently entered clinical development. Herein, the main characteristics of these new antiviral agents and the most important challenges arising with their use-namely, toxicities and rapid selection of resistance-are discussed.